KEAP1 and neuropathic pain: Overall, it is likely that decreased Keap1-Nrf2 signaling in mPFC and hippocampus is associated with anhedonia-like phenotype in rats with neuropathic pain, and that Nrf2 activators, including SFN, have therapeutic potential in patients with neuropathic pain-associated anhedonia.